imatinib + fluorouracil + oxaliplatin + leucovorin + bevacizumab

This is a combination regimen consisting of five drugs: - **Imatinib** is a small molecule tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR kinases. It is primarily used in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. - **Fluorouracil (5-FU)** is an antimetabolite chemotherapy agent that inhibits thymidylate synthase, disrupting DNA synthesis. - **Oxaliplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, inhibiting DNA replication and transcription. - **Leucovorin (folinic acid)** enhances the binding of 5-FU to thymidylate synthase, increasing its efficacy. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. This combination has been studied in metastatic colorectal cancer (mCRC), particularly as an experimental regimen where imatinib was added to standard mFOLFOX6-bevacizumab therapy[2][4]. The primary indication for this multi-drug regimen in clinical trials has been metastatic colorectal cancer.